Zynerba Pharmaceuticals, Inc. ZYNE announced the issuance of a new U.S. patent covering cannabidiol, a key compound of its product Zygel, for treating autism spectrum disorder. The U.S. Patent and Trademark Office issued US Patent No. 10,314,792, which includes claims directed to methods of treating autism spectrum disorder through the administration of a therapeutically effective amount of synthetic cannabidiol. The patent will expire in 2038.
Zygel is the first and only pharmaceutically-produced CBD formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.
In addition to autism spectrum disorder, the company initiated another phase II study last month to evaluate Zygel as a treatment for 22q11.2 deletion syndrome, a genetic disorder which may lead to mental illness.
Zynerba was awarded another method of treating patent in February, covering synthetic or purified cannabidiol for the treatment of Fragile X syndrome, a genetic disorder causing certain developmental problems in patients.
Zyne is the second company to be awarded a patent for CBD. GW Pharmaceuticals’ GWPH cannabidiol drug Epidiolex was the first drug made from the Cannabis sativa plant species to win approval from the FDA.